300149 睿智医药
已收盘 12-05 15:00:00
资讯
新帖
简况
睿智医药：实控人持股未减持
证券之星 · 12-03
睿智医药：实控人持股未减持
睿智医药（300149）披露变更董事会秘书的公告，12月1日股价下跌0.67%
证券之星 · 12-01
睿智医药（300149）披露变更董事会秘书的公告，12月1日股价下跌0.67%
睿智医药：再融资事项目前在回复深交所问询阶段
证券之星 · 11-28
睿智医药：再融资事项目前在回复深交所问询阶段
复星医药与睿智医药达成战略合作
人民财讯 · 11-25
复星医药与睿智医药达成战略合作
11月24日睿智医药现1笔折价21.21%的大宗交易 合计成交810万元
证券之星 · 11-24
11月24日睿智医药现1笔折价21.21%的大宗交易 合计成交810万元
睿智医药（300149）披露全资子公司与专业投资机构共同投资的进展公告，11月19日股价下跌2.51%
证券之星 · 11-19
睿智医药（300149）披露全资子公司与专业投资机构共同投资的进展公告，11月19日股价下跌2.51%
睿智医药发布全球首台ADC和核苷酸单体药物智造系统
中金财经 · 11-17
睿智医药发布全球首台ADC和核苷酸单体药物智造系统
股市必读：睿智医药（300149）11月14日披露最新机构调研信息
证券之星 · 11-17
股市必读：睿智医药（300149）11月14日披露最新机构调研信息
睿智医药：11月13日组织现场参观活动，国新证券、上海新丝路资本控股有限公司等多家机构参与
证券之星 · 11-14
睿智医药：11月13日组织现场参观活动，国新证券、上海新丝路资本控股有限公司等多家机构参与
新疆上市公司协会组织辖区上市公司“走进上海” 汲取经验赋能高质量发展
经济参考网 · 11-11
新疆上市公司协会组织辖区上市公司“走进上海” 汲取经验赋能高质量发展
睿智医药最新公告：子公司联合研发ADC与核苷酸单体自动化、智能化、集成化桌面式合成系统
证券之星 · 11-10
睿智医药最新公告：子公司联合研发ADC与核苷酸单体自动化、智能化、集成化桌面式合成系统
睿智医药(300149)10月31日股东户数4.21万户，较上期减少0.88%
证券之星 · 11-10
睿智医药(300149)10月31日股东户数4.21万户，较上期减少0.88%
股市必读：睿智医药（300149）10月31日披露最新机构调研信息
证券之星 · 11-03
股市必读：睿智医药（300149）10月31日披露最新机构调研信息
睿智医药：10月30日接受机构调研，东方证券、开源证券等多家机构参与
证券之星 · 10-31
睿智医药：10月30日接受机构调研，东方证券、开源证券等多家机构参与
睿智医药（300149）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 10-31
睿智医药（300149）2025年三季报简析：营收净利润同比双双增长，盈利能力上升
睿智医药(300149)10月20日股东户数4.25万户，较上期减少0.1%
证券之星 · 10-30
睿智医药(300149)10月20日股东户数4.25万户，较上期减少0.1%
图解睿智医药三季报：第三季度单季净利润同比下降1575.68%
证券之星 · 10-30
图解睿智医药三季报：第三季度单季净利润同比下降1575.68%
睿智医药：无逾期对外担保情况
证券日报 · 10-29
睿智医药：无逾期对外担保情况
睿智医药：截止到2025年10月20日，公司股东人数是42,517
证券之星 · 10-23
睿智医药：截止到2025年10月20日，公司股东人数是42,517
睿智医药（300149）披露向特定对象发行股票审核问询函回复，10月13日股价下跌1.82%
中金财经 · 10-14
睿智医药（300149）披露向特定对象发行股票审核问询函回复，10月13日股价下跌1.82%
加载更多
公司概况
公司名称：
睿智医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2010-12-22
主营业务：
睿智医药科技股份有限公司的主营业务是提供涵盖化学药研发以及生物药从早期发现到开发与规模化生产阶段的一体化服务。公司的主要产品是化学业务、药效药动业务、大分子业务。
发行价格：
28.00
{"stockData":{"symbol":"300149","market":"SZ","secType":"STK","nameCN":"睿智医药","latestPrice":9.89,"timestamp":1764918219000,"preClose":9.87,"halted":0,"volume":6024600,"delay":0,"changeRate":0.002,"floatShares":475000000,"shares":498000000,"eps":-0.3168,"marketStatus":"已收盘","change":0.02,"latestTime":"12-05 15:00:00","open":9.87,"high":9.92,"low":9.67,"amount":59167200,"amplitude":0.0253,"askPrice":9.89,"askSize":11,"bidPrice":9.88,"bidSize":1020,"shortable":0,"etf":0,"ttmEps":-0.3168,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":9.87,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":10.86,"lowLimit":8.88,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":497963992,"isCdr":false,"pbRate":3.92,"roa":"--","roe":"0.58%","epsLYR":-0.45,"committee":-0.103598,"marketValue":4925000000,"turnoverRate":0.0127,"status":0,"floatMarketCap":4693000000},"requestUrl":"/m/hq/s/300149","defaultTab":"news","newsList":[{"id":"2588046666","title":"睿智医药：实控人持股未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046666","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588046666?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:49","pubTimestamp":1764766173,"startTime":"0","endTime":"0","summary":"经核实，公司实际控制人WOO SWEE LIAN先生在此期间未减持股份。截至2025年4月30日，其持有公司55,482,062股股份；而在2025年半年度报告中，根据结算公司提供的股东名册，WOO SWEE LIAN先生持股情况分别列示为：其个人名下持有31,157,198股股份；香港中央结算有限公司持有的股份中，其以个人名义通过深港通持有24,324,864股股份；WOO SWEE LIAN先生合计仍持有公司55,482,062股股份。故在上述期间WOO SWEE LIAN先生未进行任何减持操作，不涉及对外公告事项，感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"gpt_icon":0},{"id":"2588049775","title":"睿智医药（300149）披露变更董事会秘书的公告，12月1日股价下跌0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049775","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588049775?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:38","pubTimestamp":1764599917,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，睿智医药报收于10.32元，较前一交易日下跌0.67%，最新总市值为51.39亿元。该股当日开盘10.39元，最高10.43元，最低10.3元，成交额达6221.06万元，换手率为1.27%。公司于2025年12月1日召开第六届董事会第十四次会议，审议通过聘任高莹莹女士为新任董事会秘书，任期至第六届董事会届满。高莹莹女士已取得深交所董事会秘书培训证明，具备任职资格。公司同时披露了董事会秘书新的联系方式。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100037346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"gpt_icon":0},{"id":"2586829757","title":"睿智医药：再融资事项目前在回复深交所问询阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2586829757","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586829757?lang=zh_cn&edition=full","pubTime":"2025-11-28 20:52","pubTimestamp":1764334335,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司定向增发已一年多，目前已进行那一步何时能完成定向增发睿智医药回复：尊敬的投资者您好！公司再融资事项目前在回复深交所问询阶段，相关工作在有序推进中。公司将根据进展情况，严格按照相关法律法规的规定和要求及时履行信息披露义务。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800036354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["162717","BK0077","300149","BK0216"],"gpt_icon":0},{"id":"2586474186","title":"复星医药与睿智医药达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2586474186","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586474186?lang=zh_cn&edition=full","pubTime":"2025-11-25 23:01","pubTimestamp":1764082916,"startTime":"0","endTime":"0","summary":"人民财讯11月25日电，11月25日，复星医药与睿智医药在上海举行战略合作框架协议签约仪式。复星医药高级副总裁兼全球研发中心首席执行官李翔表示，未来，借助与睿智医药全链条研发服务能力，有望进一步提升复星医药在多种类型药物研发领域的效率与质量，加速创新成果转化，巩固我们在创新医药领域的竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511253574517765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","BK0239","BK0028","BK0187","BK0077","BK0196","BK1515","BK1593","BK1191","300149","BK0216","BK0188","02196","BK0183","BK0175","BK0060","BK0096","600196"],"gpt_icon":0},{"id":"2585468837","title":"11月24日睿智医药现1笔折价21.21%的大宗交易 合计成交810万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468837","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585468837?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:41","pubTimestamp":1763977274,"startTime":"0","endTime":"0","summary":"证券之星消息，11月24日睿智医药发生大宗交易，交易数据如下：大宗交易成交价格8.1元，相对当日收盘价折价21.21%，成交100万股，成交金额810万元，买方营业部为中信证券股份有限公司衡阳祝融路证券营业部，卖方营业部为华福证券有限责任公司江门迎宾大道中证券营业部。近三个月该股共发生1笔大宗交易，合计成交1.0万手，折价成交1笔。截至2025年11月24日收盘，睿智医药报收于10.28元，上涨1.68%，换手率1.52%，成交量7.23万手，成交额7391.86万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400022220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300149","BK0216"],"gpt_icon":0},{"id":"2584947523","title":"睿智医药（300149）披露全资子公司与专业投资机构共同投资的进展公告，11月19日股价下跌2.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584947523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584947523?lang=zh_cn&edition=full","pubTime":"2025-11-19 22:26","pubTimestamp":1763562386,"startTime":"0","endTime":"0","summary":"截至2025年11月19日收盘，睿智医药报收于10.87元，较前一交易日下跌2.51%，最新总市值为54.13亿元。该股当日开盘11.11元，最高11.18元，最低10.74元，成交额达1.13亿元，换手率为2.18%。截至公告日，北海睿智已缴付首期出资额1160万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900040067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"gpt_icon":0},{"id":"2584629325","title":"睿智医药发布全球首台ADC和核苷酸单体药物智造系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629325","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584629325?lang=zh_cn&edition=full","pubTime":"2025-11-17 21:40","pubTimestamp":1763386801,"startTime":"0","endTime":"0","summary":"11月17日，“超限·智造——ADC和核苷酸单体药物智造系统发布会”在上海张江举行。睿智医药联合华东师范大学推出全球首台适用于ADC与核苷酸亚磷酰胺单体合成的药物智造系统，为创新药产业高质量发展注入关键动能。据介绍，此次发布的ADC药物智造系统TAO-AG1采用微流控与AI智能控制技术，体积仅480×390×500mm，实现空间的高效利用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251117/31802762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300149","BK0216","BK0077","BK4231","ADC","BK4080"],"gpt_icon":0},{"id":"2584604586","title":"股市必读：睿智医药（300149）11月14日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2584604586","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584604586?lang=zh_cn&edition=full","pubTime":"2025-11-17 01:10","pubTimestamp":1763313023,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，睿智医药报收于11.67元，上涨3.73%，换手率6.38%，成交量30.27万手，成交额3.51亿元。来自机构调研要点：公司力争2025年实现营业收入增长率不低于15%，净利润转正。答：公司于2025年4月发布《2025年限制性股票激励计划（草案）》，并于2025年7月11日为首次授予日，授予价格为3.05元/股，向123名激励对象授予4,456.00万股限制性股票。相关股份支付费用将按解除限售/归属安排比例摊销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700000417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2583257223","title":"睿智医药：11月13日组织现场参观活动，国新证券、上海新丝路资本控股有限公司等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2583257223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583257223?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:31","pubTimestamp":1763116309,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月14日睿智医药发布公告称公司于2025年11月13日组织现场参观活动，国新证券、上海新丝路资本控股有限公司、上海伊隆博轩企业管理合伙企业、上海星良投资管理有限公司、上海盛石资本管理有限公司、上海天戈投资管理有限公司、投资者参与。融资融券数据显示该股近3个月融资净流出6605.11万，融资余额减少；融券净流入1.83万，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400032674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","399429","BK0216","161027","BK0077","502026"],"gpt_icon":0},{"id":"2582363236","title":"新疆上市公司协会组织辖区上市公司“走进上海” 汲取经验赋能高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2582363236","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582363236?lang=zh_cn&edition=full","pubTime":"2025-11-11 19:25","pubTimestamp":1762860300,"startTime":"0","endTime":"0","summary":"近日，新疆上市公司协会组织辖区27家上市公司及相关机构40余人赴上海开展学习交流活动。下一步，新疆上市公司协会将持续聚焦企业发展需求，常态化组织各类学习交流活动，推动辖区企业对标行业先进、强化内外联动，为新疆资本市场健康发展和地方经济高质量发展注入更强动力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-11/doc-infwzrrx4328808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000877","BK0235","BK0029","BK0077","BK0108","BK0019","002517","688798","BK0044","300149","BK0012","BK0149","SGXZ81163826.USD","BK0132","BK0214","BK0083","BK0276","BK0183","BK0000","SGXZ49509284.SGD","BK0216","BK0217","LU1979443071.USD","BK0094","BK0028","BK0188","000166","BK0010","BK0187","LU1934453819.USD"],"gpt_icon":0},{"id":"2582827770","title":"睿智医药最新公告：子公司联合研发ADC与核苷酸单体自动化、智能化、集成化桌面式合成系统","url":"https://stock-news.laohu8.com/highlight/detail?id=2582827770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582827770?lang=zh_cn&edition=full","pubTime":"2025-11-10 19:01","pubTimestamp":1762772491,"startTime":"0","endTime":"0","summary":"睿智医药(300149.SZ)公告称，近期，公司全资子公司上海睿智医药研究集团有限公司与华东师范大学（简称“华东师大”）成功联合自主研发了抗体偶联药物（ADC）与核苷酸单体自动化、智能化、集成化桌面式合成系统，可以实现从实验室研发到产业生产的无缝衔接与范式重构。ADC与核苷酸单体自动化、智能化、集成化桌面式合成系统的运用，可以显著缩短研发周期，提升研发效率，助力公司为客户提供更优质的服务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000027311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2582082960","title":"睿智医药(300149)10月31日股东户数4.21万户，较上期减少0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582082960","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582082960?lang=zh_cn&edition=full","pubTime":"2025-11-10 17:23","pubTimestamp":1762766609,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2025年10月31日公司股东户数为4.21万户，较10月20日减少375.0户，减幅为0.88%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至10月31日，医疗服务行业平均股东户数为4.6万户。从股价来看，2025年10月20日至2025年10月31日，睿智医药区间涨幅为3.02%，在此期间股东户数减少375.0户，减幅为0.88%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000022800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0216","BK0077"],"gpt_icon":0},{"id":"2580988258","title":"股市必读：睿智医药（300149）10月31日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2580988258","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580988258?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:42","pubTimestamp":1762130536,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，睿智医药报收于11.59元，上涨4.7%，换手率4.79%，成交量22.73万手，成交额2.6亿元。前三季度实现营业收入 8.17亿元，同比增长 13.68%；第三季度单季实现营业收入2.83亿元，增长 11.72%。剔除股权激励费用影响后，前三季度归母净利润为4,273万元，扣非净利润 2,129 万元；第三季度归母净利润 1,735 万元，盈利能力显著改善。答：公司波士顿实验室建设进展顺利，研发团队已组建完成，预计将于 11月起正式开展实验项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300002249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300149","BK0077"],"gpt_icon":0},{"id":"2579445218","title":"睿智医药：10月30日接受机构调研，东方证券、开源证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2579445218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579445218?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:07","pubTimestamp":1761905243,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年10月31日睿智医药发布公告称公司于2025年10月30日接受机构调研，东方证券、开源证券、国盛证券、兴业证券、华安证券、招商证券、华福证券参与。前三季度实现营业收入 8.17亿元，同比增长 13.68%；第三季度单季实现营业收入2.83亿元，增长 11.72%。答：公司波士顿实验室建设进展顺利，研发团队已组建完成，预计将于 11月起正式开展实验项目。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100039049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1564","BK0028","161027","600958","03958","300149","BK0183","BK1147","BK0276","BK0077","BK0216","BK0012"],"gpt_icon":0},{"id":"2579101112","title":"睿智医药（300149）2025年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2579101112","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579101112?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:48","pubTimestamp":1761864483,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期睿智医药发布2025年三季报。截至本报告期末，公司营业总收入8.17亿元，同比上升13.68%，归母净利润709.13万元，同比上升111.5%。本报告期睿智医药盈利能力上升，毛利率同比增幅43.32%，净利率同比增幅110.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100009846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149"],"gpt_icon":0},{"id":"2579111330","title":"睿智医药(300149)10月20日股东户数4.25万户，较上期减少0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579111330","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579111330?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:43","pubTimestamp":1761817437,"startTime":"0","endTime":"0","summary":"证券之星消息，近日睿智医药披露，截至2025年10月20日公司股东户数为4.25万户，较9月30日减少41.0户，减幅为0.1%。在医疗服务行业个股中，睿智医药股东户数低于行业平均水平，截至10月20日，医疗服务行业平均股东户数为4.65万户。从股价来看，2025年9月30日至2025年10月20日，睿智医药区间跌幅为1.4%，在此期间股东户数减少41.0户，减幅为0.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000034186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149","BK0077","BK0216"],"gpt_icon":0},{"id":"2579818742","title":"图解睿智医药三季报：第三季度单季净利润同比下降1575.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579818742","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579818742?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:07","pubTimestamp":1761764857,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药2025年三季报显示，前三季度公司主营收入8.17亿元，同比上升13.68%；归母净利润709.13万元，同比上升111.5%；扣非净利润-1434.95万元，同比上升79.22%；其中2025年第三季度，公司单季度主营收入2.83亿元，同比上升11.72%；单季度归母净利润-1829.08万元，同比下降1575.68%；单季度扣非净利润-2114.18万元，同比下降322.61%；负债率35.77%，投资收益1383.54万元，财务费用518.27万元，毛利率27.55%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300149"],"gpt_icon":0},{"id":"2579790087","title":"睿智医药：无逾期对外担保情况","url":"https://stock-news.laohu8.com/highlight/detail?id=2579790087","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579790087?lang=zh_cn&edition=full","pubTime":"2025-10-29 22:16","pubTimestamp":1761747360,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月29日晚间，睿智医药发布公告称，公司及控股子公司无逾期对外担保情况，无涉及诉讼的担保金额以及因担保被判决败诉而应承担的担保金额。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-29/doc-infvqrtz3095974.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-29/doc-infvqrtz3095974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0077","BK0216","300149"],"gpt_icon":0},{"id":"2577349628","title":"睿智医药：截止到2025年10月20日，公司股东人数是42,517","url":"https://stock-news.laohu8.com/highlight/detail?id=2577349628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577349628?lang=zh_cn&edition=full","pubTime":"2025-10-23 08:36","pubTimestamp":1761179771,"startTime":"0","endTime":"0","summary":"证券之星消息，睿智医药(300149)10月22日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘，你好!请问截止至2025年10月20日，公司股东人数总数是多少?谢谢!睿智医药回复：尊敬的投资者，您好！感谢对公司的关注！截止到2025年10月20日，公司股东人数是42,517。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102300006249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","BK0077","300149"],"gpt_icon":0},{"id":"2575341622","title":"睿智医药（300149）披露向特定对象发行股票审核问询函回复，10月13日股价下跌1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575341622","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575341622?lang=zh_cn&edition=full","pubTime":"2025-10-14 08:06","pubTimestamp":1760400382,"startTime":"0","endTime":"0","summary":"同日，睿智医药发布公告称，公司已于近日完成对深圳证券交易所《关于睿智医药科技股份有限公司申请向特定对象发行股票的审核问询函》的回复，并会同相关中介机构对问询函所提问题进行了研究和落实，同时更新了募集说明书等申请文件。公告指出，本次向特定对象发行股票事项尚需经深交所审核通过，并获得中国证监会同意注册后方可实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251014/31703369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300149","BK0216","BK0077"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765133076580,"stockEarnings":[{"period":"1week","weight":-0.0481},{"period":"1month","weight":-0.113},{"period":"3month","weight":-0.2496},{"period":"6month","weight":0.0185},{"period":"1year","weight":0.4417},{"period":"ytd","weight":0.5405}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"睿智医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"39753人(较上一季度减少2.04%)","perCapita":"11937股","listingDate":"2010-12-22","address":"广东省江门市江海区胜利南路164号","registeredCapital":"49796万元","survey":" 睿智医药科技股份有限公司的主营业务是提供涵盖化学药研发以及生物药从早期发现到开发与规模化生产阶段的一体化服务。公司的主要产品是化学业务、药效药动业务、大分子业务。","listedPrice":28},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"睿智医药,300149,睿智医药股票,睿智医药股票老虎,睿智医药股票老虎国际,睿智医药行情,睿智医药股票行情,睿智医药股价,睿智医药股市,睿智医药股票价格,睿智医药股票交易,睿智医药股票购买,睿智医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"睿智医药(300149)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供睿智医药(300149)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}